4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down – What’s Next?

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) gapped down before the market opened on Friday . The stock had previously closed at $8.69, but opened at $8.44. 4D Molecular Therapeutics shares last traded at $8.8840, with a volume of 396,555 shares traded.

Analyst Ratings Changes

A number of research firms have recently weighed in on FDMT. Leerink Partners reiterated an “outperform” rating and set a $17.00 price target on shares of 4D Molecular Therapeutics in a report on Friday, October 31st. Morgan Stanley raised shares of 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research report on Friday, November 7th. Royal Bank Of Canada lifted their price target on shares of 4D Molecular Therapeutics from $26.00 to $32.00 and gave the company an “outperform” rating in a research report on Tuesday, November 11th. Barclays decreased their price objective on shares of 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, November 11th. Finally, Chardan Capital reiterated a “buy” rating and issued a $26.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $28.70.

4D Molecular Therapeutics Trading Up 2.8%

The firm’s fifty day simple moving average is $10.68 and its 200 day simple moving average is $7.47. The company has a market cap of $510.50 million, a price-to-earnings ratio of -2.38 and a beta of 2.96.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Monday, November 10th. The company reported ($1.01) EPS for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.01. The business had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.40 million. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%. As a group, sell-side analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.

Insider Transactions at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Friday, October 24th. The stock was sold at an average price of $12.00, for a total transaction of $32,136.00. Following the transaction, the insider owned 3,594 shares of the company’s stock, valued at $43,128. The trade was a 42.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 10,763 shares of company stock worth $109,415. Company insiders own 9.60% of the company’s stock.

Institutional Trading of 4D Molecular Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd purchased a new stake in shares of 4D Molecular Therapeutics during the first quarter worth approximately $39,000. Wexford Capital LP acquired a new position in 4D Molecular Therapeutics in the 3rd quarter valued at $41,000. Los Angeles Capital Management LLC purchased a new position in 4D Molecular Therapeutics during the 2nd quarter worth $42,000. Quadrature Capital Ltd acquired a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter worth $42,000. Finally, Farther Finance Advisors LLC lifted its stake in shares of 4D Molecular Therapeutics by 117.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock worth $43,000 after acquiring an additional 2,674 shares during the period. 99.27% of the stock is owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.